NOD2/CARD15 does not influence response to infliximab in Crohn’s disease

Gastroenterology

Volumn 123, Issue 1, 2002, Pages 106-111

  Vermeire, Severine ^a   Louis, Edouard ^b   Rutgeerts, Paul ^a   De Vos, Martine ^c   Van Gossum, Andre ^d   Belaiche, Jacques ^b   Pescatore, Paul ^e   Fiasse, Rene ^f   Pelckmans, Paul ^g   Vlietinck, Robert ^h   Merlin, Françoise ⁱ   Zouali, Habib ⁱ   Thomas, Gilles ^i,j   Hugot, JeanPierre ^i,l   Colombel, JeanFrederic ^k  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d ERASME HOSPITAL   (Belgium)

^e Department of Gastroenterology   (United States)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^h UNIVERSITY OF LEUVEN   (Belgium)

ⁱ FONDATION JEAN DAUSSET CEPH   (France)

^j HÔPITAL SAINT ANTOINE   (France)

^k LILLE UNIVERSITY HOSPITAL   (France)

^l HÔPITAL ROBERT DEBRÉ   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; INFLIXIMAB; PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COLON MUCOSA; CONTROLLED STUDY; CROHN DISEASE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; INTESTINE BIOPSY; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE CULTURE; TREATMENT OUTCOME;

EID: 0036305537     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.34172     Document Type: Article

References (15)

1. The epidemiology of idiopathic inflammatory bowel disease
2. Genetic epidemiology in inflammatory bowel disease
3. Association of NOD2/CARD15 leucin-rich repeat variants with susceptibility to Crohn disease
4. A frameshift mutation in NOD2/CARD15 associated with susceptibility to Crohn disease
5. NOD2/CARD15, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-κB
6. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn disease
7. Infliximab for the treatment of fistulas in patients with Crohn’s disease
8. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease
9. Pharmcacogenetic association between the TNF receptor 2 genotype and response to infliximab treatment in Crohn’s disease
10. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn’s disease
11. Association between insertion mutation in NOD2/CARD15 gene and Crohn’s disease in German and British populations
12. Use of coculture of colonic biopsies to investigate the release of eicosanoids by inflamed and uninflamed mucosa from patients with inflammatory bowel disease
13. Microscopic activity in ulcerative colitis: What does it mean?
14. Increased production of tumor necrosis factor-α, interleukin-β, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn’s disease
15. Mapping of a susceptibility locus for Crohn’s disease on chromosome 16